Search

Your search keyword '"Arndt-Christian Mueller"' showing total 16 results

Search Constraints

Start Over You searched for: Author "Arndt-Christian Mueller" Remove constraint Author: "Arndt-Christian Mueller"
16 results on '"Arndt-Christian Mueller"'

Search Results

1. Online Adaptive MR-Guided Ultrahypofractionated Radiotherapy of Prostate Cancer on a 1.5 T MR-Linac: Clinical Experience and Prospective Evaluation

2. Dose-escalated radiotherapy with simultaneous integrated boost for bone metastases in selected patients with assumed favourable prognosis

Catalog

Books, media, physical & digital resources

3. Therapiemöglichkeiten des Seminoms im klinischen Stadium I und II unter Berücksichtigung der Langzeittoxizität

4. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT

5. Performance of a Genomic Classifier (GC) Within a Phase 3 Randomized Trial of Dose Escalated Salvage Radiotherapy (SRT) After Radical Prostatectomy (RP)

6. Dose-intensified versus conventional dose-salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: Six-year outcomes of the SAKK 09/10 randomized phase III trial

7. PH-0487: Analysis of treatment times and workflow at a 1.5 T MR Linac

8. Contouring Quality and Adherence to EORTC-based Protocol Guidelines in the Randomized Phase III SAKK 09/10 Trial for Postoperative Prostate Cancer Radiotherapy: Implications for Treatment Quality and Future Clinical Trials

9. Treatment compliance and early toxicity in SAKK 01/10: Single-dose carboplatin and involved-node radiotherapy for treatment of stage IIA/B seminoma

10. Definitive radiotherapy and Single-Agent radiosensitizing Ifosfamide in Patients with localized, irresectable Soft Tissue Sarcoma: A retrospective analysis

11. Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: First results of the randomized trial SAKK 09/10

12. Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy

14. PV-0428: Factor 2.5 radiosensitivity difference determined by ex vivo γH2AX assay in prostate cancer patients